BusinessHealthScienceTechnologyTop Stories
Trending

Europe Blood Screening Market is projected to register a healthy CAGR of 9.3% in the forecast by 2025 | Key Players-BD , Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc. , BioMérieux SA , Beckman Coulter, Inc.

Europe Blood Screening Market

Europe Blood Screening Market report is also useful when a new product is launched on the market or the company is distributed on a regional or global basis. In addition, the report analyzes common market conditions such as price of the product, profit, capacity, production, supply, demand, and growth rate of the market, giving businesses a hand in deciding multiple strategies. The Europe Blood Screening Market report for all industry is a comprehensive analysis of the industry study. The report sets out all the CAGR values for the 2018-2025 forecast period. The report sets out all the CAGR values for the 2018-2025 forecast period.

Competitive Analysis: Europe Blood Screening Market

Some of the prominent participants operating in this market are Enzo Biochem Inc. , Meridian Bioscience, Inc. , BD , Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc. , BioMérieux SA , Beckman Coulter, Inc. , Abbott , F. Hoffmann-La Roche Ltd , Cepheid , GRIFOLS INTERNATIONAL, S.A. , Siemens AG (Germany), Ortho Clinical Diagnostics , Immucor, Inc., Hologic Inc. , among others.

Europe Blood Screening Market is projected to register a healthy CAGR of 9.3% in the forecast period of 2018 to 2025.

Market Segmentation:

The Global Blood Screening Market is categorized based on the basis of products & services, technology, disease type and end user.

  • On the basis of product & services the market is segmented into reagents & kits, instruments and also software & services. Reagents & kits are further sub segmented into NAT reagents & kits, ELISA reagents & kits and other reagents. NAT reagents are further sub segmented into enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides and solutions and labeling and detection reagents. ELISA reagents & kits is further sub segmented into immunosorbents, controls, conjugates (antigen or antibody-conjugated enzyme), substrates (of enzymes) and sample diluents and wash solutions. Instruments segment is further segmented into instruments, product type and instruments, purchase type. In 2017, reagents & kits segment are expected to dominate the global blood screening market growing at the CAGR of 9.4% in the forecast period of 2018 to 2025.
  • On the basis of technology the market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others. Nucleic acid test is further sub segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) are further segmented into ELISA market, by platform, ELISA market, by generation. ELISA Market, By Platform is further sub segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA) and colorimetric immunoassay (CI). ELISA market, by generation is further segmented into first-generation ELISA, second-generation ELISA, third-generation ELISA and fourth-generation & above. In 2017, enzyme-linked immunosorbent assay (ELISA) segment is expected to dominate the global blood screening market growing at the CAGR of 9.8% in the forecast period of 2018 to 2025.
  • On the basis of disease type, the market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and others. In 2017, oncology segment is expected to dominate the global blood screening market growing at the highest CAGR of 10.3% in the forecast period of 2018 to 2025.
  • On the basis of end user the market is segmented into hospitals, clinics, diagnostic centers, blood bank and ambulatory surgical cenetrs. In 2017, diagnostic centers segment is expected to dominate the global blood screening market growing at the highest CAGR of 10.4%in the forecast period of 2018 to 2025.

Product launch: Europe Blood Screening Market

  • In March 2018, Bio-Rad Laboratories, Inc. launched IncRNA Workflow, a RT-qPCR workflow which is used optimized for highly sensitive and specific quantification of long noncoding RNAs (lncRNAs) for gene expression analysis. The workflow provides a streamlined, cost-effective alternative to RNA-Seq for lncRNA discovery and validation
  • In June 2018, Thermo Fisher Scientific launched Oncomine TCR Beta-SR Assay. It is a new next-generation sequencing (NGS) solution in the field of immuno-oncology research. This helped company to expand their business by enhancing their product portfolio.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us-

Data Bridge Market Research

US: +1-888-387-2818

Email: sopan.gedam@databridgemarketresearch.com

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *